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Background: Lucid dreams are frequently pleasant and training techniques have been developed to teach dreamers to 
induce them. In addition, the induction of lucid dreams has also been used as a way to ameliorate nightmares. On the 
other hand, lucid dreams may be associated with psychiatric conditions, including Post-Traumatic Stress Disorder 
(PTSD) and Reward Deficiency Syndrome-associated diagnoses. In the latter conditions, lucid dreams can assume an 
unpleasant and frequently terrifying character. Case presentations: We present two cases of dramatic alleviation of ter-
rifying lucid dreams in patients with PTSD. In the first case study, a 51-year-old, obese woman, diagnosed with PTSD 
and depression, had attempted suicide and experienced terrifying lucid nightmares linked to sexual/physical abuse 
from early childhood by family members including her alcoholic father. Her vivid “bad dreams” remained refractory 
in spite of 6 months of treatment with Dialectical Behavioral Therapy (DBT) and standard pharmaceutical agents 
which included prazosin, clonidie and Adderall. The second 39-year-old PTSD woman patient had also suffered from 
lucid nightmares. Results: The medication visit notes reveal changes in the frequency, intensity and nature of these 
dreams after the complex putative dopamine agonist KB220Z was added to the first patient’s regimen. The patient re-
ported her first experience of an extended period of happy dreams. The second PTSD patient, who had suffered from 
lucid nightmares, was administered KB220Z to attenuate methadone withdrawal symptoms and incidentally reported 
dreams full of happiness and laughter. Conclusions: These cases are discussed with reference to the known effects of 
KB220Z including enhanced dopamine homeostasis and functional connectivity of brain reward circuitry in rodents 
and humans. Their understanding awaits intensive investigation involving large-population, double-blinded studies. 
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“The implication is that fantasy and dreams are part 
of a single continuing fantasy process which is subject 
to certain transformations imposed by physiological 
and stimulus events. It is unnecessary to sleep in order 
to generate dream-like ideation, and, apparently, it is 
unnecessary to be awake in order to produce relatively 
coherent, undream-like ideation.”
Eric Klinger (1971, p. 57)
INTRODUCTION
Throughout the 20th century, dreaming was central to lead-
ing psychotherapeutic approaches to mental disorders. Psy-
chodynamic models of the mind were inspired by the work 
of Sigmund Freud’s Interpretation of Dreams (Schredl, 
Bohusch, Kahl, Mader & Somesan, 2000). Based on his 
experience, Freud suggested that the unconscious founda-
tions of most symptom understanding could be illuminated 
by an accurate evaluation of reported dreams. At the dawn 
of the 21st century these conceptualizations were challenged 
by neuroscientists who favored mechanistic models of brain 
dysfunction. 
A generation of psychiatrists has turned to psychiatric bi-
ology for a more scientific, rigorous, and reliable phenotype 
to understand mental disorders. A new psychological tech-
niques as well as pharmacotherapy’s emerged as the current 
cornerstone of treatment for mental disorders (Fusar-Poli et 
al., 2007). Importantly, nightmares are a prevalent parasom-
nia associated with a range of psychiatric conditions, and 
many psychiatrists continue to embrace neo-psychoanalytic 
speculations concerning their meaning. However, new ad-
vances in neuroscience, especially neuroimaging techniques 
and progress in neurogenetics, are helping to supplement 
the quest for answers regarding this complex phenomenon. 
Empirical research has over the years stipulated some 
type of emotionally adaptive function for dreaming, e.g., 
image-contextualization, affect de-somatization, mood 
regulation, or fear extinction. Specifically, nightmares have 
been considered by many to be an intensified expression of 
an emotionally adaptive function. Moreover, Kovachy et 
al. (2013) discussed the role of sleep disturbances in Post-
Traumatic Stress Disorder (PTSD), suggesting that night-
mares in children and adolescents exposed to trauma and/
or diagnosed with PTSD have significant loading. Nielsen 
and Levin (2007) suggested an affective network dysfunc-
tion (AND) model that integrates the tenets of prior models 
in proposing that nightmares reflect problems with the fear 
extinction function of dreaming. According to the authors, 
this new model accounts for a wide range of dysphoric 
dream imagery that includes bad dreams, idiopathic night-
mares and post-traumatic nightmares. As such, it seems to 
incorporate recent findings from brain imaging in the areas 
of sleep physiology, PTSD, anxiety disorders and the con-
solidation and extinction of fear memories.
Spoormaker, Schredl and van den Bout (2005) correctly 
pointed out that it is important to discriminate nightmares as 
PTSD and non-PTSD related in terms of a patient’s history 
or other neurobiological defined parameters. Specifically, it is 
necessary to distinguish idiopathic nightmares from posttrau-
matic nightmares, which are part of a posttraumatic stress reac-
tion or disorder that may result from experiencing a traumatic 
event. Both types of nightmares have been associated with 
an elevated level of periodic limb movements, although only 
posttraumatic nightmares seem to be related to more frequent 
and longer nocturnal awakenings. Furthermore, Mellman, Da-
vid, Kulick-Bell, Hebding and Nolan (1995) believe that bad 
dreams may be the result of previous psychiatric problems 
such as depression when exposed to a traumatic event, indicat-
ing pre-existing conditions such as neurogenetic antecedents 
to these psychiatric conditions as has been recently observed 
for depression (Pearson-Fuhrhop et al., 2014).
To determine if depression per se is a major factor in 
terms of frequent nightmares compared to victims of ex-
traordinary stress such as Nazi Holocaust survivors, Rosen, 
Reynolds, Yeager, Houck and Hurwitz (1991) evaluated 42 
survivors, 37 depressed patients, and 54 healthy subjects 
of about the same age in terms of sleep impairment. Survi-
vors had significantly more frequent awakenings due to bad 
dreams and had less loss of enthusiasm than the depressed 
subjects. Sleep disturbances and frequency of nightmares 
were significantly and positively correlated with the dura-
tion of the survivors’ internment in concentration camps. 
Importantly, the Nazi Holocaust survivors’ frequent night-
mares remained a considerable problem even 45 years after 
liberation.
Nightmares as a function of neurotransmission
Currently, we do not understand fully the mechanism(s) of 
nightmares, why people have them and what the neurologi-
cal causes of this sleep impairment are, despite a signifi-
cant literature on the neurobiology of dreams. One theory 
suggests that the hippocampus is involved, and contextual 
memory is impaired in dreams occurring during para-
doxical sleep. Accordingly, this impairment is caused by 
increased concentrations of acetylcholine, dopamine, and 
cortisol, as well as the absence of serotonin and noradrena-
line (Sil’kis, 2010). Specifically, paradoxical sleep occurs 
via the activation of cholinergic neurons in the peduncu-
lopontine nucleus as a result of suppression of their inhi-
bition from the output basal ganglia nuclei. Sil’kis further 
suggested that any neurotransmitter or neuropeptide able 
to promote long-term potentiation in all components of the 
polysynaptic pathway through the hippocampus, especially 
at CA1 and CA3, can improve episodic memory and reduce 
nightmares. He also suggested that these disruptions in-
volve variations in acetylcholine, dopamine, noradrenaline, 
serotonin, and glutamate concentrations. Importantly, this 
disinhibition is induced by activation of dopaminergic cells 
by pedunculopontine neurons. It was further suggested that 
there is a subsequent rise in dopamine concentration in the 
input basal ganglia structure striatum, and modulation of 
the efficacy of cortico-striatal inputs may be critical for the 
development of nightmares (Sil’kis, 2006). Moreover, in 
the absence of signals from the retina, a disinhibition of 
neurons in the pedunculopontine nucleus and superior col-
liculus allows them to excite neurons in the lateral genicu-
late body and other thalamic nuclei projecting to the pri-
mary and higher visual cortical areas, prefrontal cortex, and 
back into the striatum. Thus, dreams as visual images and 
motor hallucinations are the result of an increase in activ-
ity of specifically selected groups of thalamic and neocorti-
cal neurons. The involvement of dopamine is paramount in 
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that its homeostasis provides synaptic transmission effica-
cy during the circulation of signals in closed interconnected 
loops, each of which includes one of the visual cortical ar-
eas, one of the thalamic nuclei, limbic areas and a region of 
the basal ganglia.
Additionally, Gottesmann (2006) suggested that in schiz-
ophrenia, the rapid eye movement (REM) dreaming sleep 
stage is characterized by common intracerebral disconnec-
tions, disturbed responsiveness, and sensory differentiation 
processes. Simply, disinhibition of superior colliculus neu-
rons and their excitation by the pedunculopontine nucleus 
lead to an appearance of REM during paradoxical sleep. In 
fact, during REM sleep, the principal dreaming stage, the 
cortex is activated but significantly disinhibited, since all 
aminergic neurons are silent except the dopaminergic ones 
(Gottesmann & Joncas, 2000).
Solms (2000) in an attempt to unravel sleep disturbanc-
es, especially “bad dreams”, pointed out that dreaming and 
REM sleep are dissociable states, and that dreaming is con-
trolled by forebrain mechanisms, that cholinergic brain stem 
activity controls the REM state and as such can generate 
the psychological phenomena of dreaming only through the 
mediation of a second, probably dopaminergic, forebrain 
mechanism. Moreover, dreaming can be manipulated by 
dopamine agonists and antagonists with no concomitant 
change in REM frequency, duration, and density. 
In fact, dreaming is obliterated by focal lesions along 
a specific (probably dopaminergic) forebrain pathway and 
these lesions do not have any appreciable effect on REM 
frequency, duration, and density. As such, Solms’ suggested 
that the forebrain mechanism in question is the final com-
mon pathway to dreaming and that the brainstem oscillator 
that controls the REM state is just one of the many arousal 
triggers that can activate this forebrain mechanism. 
Lucid dreams, the subject of these case histories, are 
a special form of dream life, in which the dreamer is fre-
quently aware that he/she is dreaming, can stop/re-start the 
dreams, depending on the pleasantness or unpleasant nature 
of the dream, and experiences the dream as if he/she were 
fully awake.
Based on the clinical experience of one of us (TM), it was 
decided to incorporate a well-researched putative complex 
safe putative dopamine agonist known as KB220Z (Blum, 
Oscar-Berman et al., 2012) in a diagnosed PTSD patient’s 
treatment plan to determine if this complex would provide 
any beneficial effects to combat reoccurring lucid nightmares 
(“bad dreams”) refractive with other pharmaceutical agents. 
Standard treatment options
In an attempt to provide medical guidelines to treat unwant-
ed “bad dreams” especially in PTSD patients, Aurora et al. 
(2010) recommended the following treatment options:
– Prazosin is recommended for treatment of PTSD-
associated nightmares. 
– Image Rehearsal Therapy is recommended for treat-
ment of nightmare disorder. 
– Systematic Desensitization and Progressive Deep 
Muscle Relaxation training are suggested for treat-
ment of idiopathic nightmares. 
– Clonidine may be considered for treatment of PTSD-
associated nightmares.
– The following medications may be considered for 
treatment of PTSD-associated nightmares, but sup-
porting data are sparse: trazodone, atypical antipsy-
chotic medications, topiramate, low dose cortisol, 
fluvoxamine, triazolam and nitrazepam, phenelzine, 
gabapentin, cyproheptadine, and tricyclic antidepres-
sants. Nefazodone is not recommended as first line 
therapy for nightmare disorder because of the in-
creased risk of hepatotoxicity (Level C).
– The following behavioral therapies may be consid-
ered for treatment of PTSD-associated nightmares 
based on low-grade evidence: Exposure, Relaxation, 
and Rescripting Therapy; Sleep Dynamic Therapy; 
Hypnosis; Eye-Movement Desensitization and Re-
processing; and the Testimony Method.
– The following behavioral therapies may be consid-
ered for treatment of nightmare disorder based on 
low-grade evidence: Lucid Dreaming Therapy and 
Self-Exposure Therapy.
– Venlafaxine is not suggested for treatment of PTSD-
associated nightmares. No recommendation is made 
regarding clonazepam and individual psychotherapy 
because of sparse data.
CASE PRESENTATION ONE
AC at the time of the initial evaluation was a 51-year-old 
woman allergic to both iodine and fish, living with her 
daughter, brother, and sister-in-law. She was receiving cit-
alopram and seroquel for depression (10/10 highest rating) 
and was a thyroid ectomized obese individual. The patient 
stated she had been in psychotherapy for two years but never 
discussed any abuse in her marriage. She denied any psychi-
atric hospitalizations. The onset of her psychological symp-
toms began when she was living in Puerto Rico in 2008, 
while divorcing her second husband. Her house caught on 
fire, and she was involved in a motor vehicle accident with-
out loss of consciousness. She did not receive any support 
from her company at that time. She also reported that her 
first husband physically, sexually, and verbally abused her.
Abuse history
The patient was sexually abused by two uncles involving 
sexual intercourse, as well as by a cousin during her child-
hood. With respect to physical abuse, she stated there was 
extreme violence in the home, and her mother was frequent-
ly beaten by her father while they lived in New York City. 
She herself was beaten at five years of age by her father 
and never told her mother. She was also emotionally abused 
by her cousins. The patient was the victim of physical vio-
lence by her first husband and verbal abuse by her second 
husband. The patient attempted suicide three times, once 
involving crashing her motorcycle into a car. She never 
revealed this in therapy. The patient denied any history of 
legal involvement.
Family psychiatric history
One cousin committed suicide, and there were numerous 
other suicides in the family. Her father was an alcoholic. 
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(Later, it was determined that the father had presumed Tou-
rette’s Syndrome, in view of his frequent throat-clearing and 
motor mannerisms). The patient’s mother was 73 years old 
and described as “quiet and submissive”. During her mar-
riage, the mother was beaten and stabbed. She did not en-
gage in any activities nor was she affectionate towards the 
patient, when the latter was 5–6 years of age. The patient’s 
father is deceased and was described as “mean, violent, and 
very scary”. AC had not had any contact with her father un-
til three years prior to his death, when he apologized for 
his abuse. She stated that her father died of cancer. She has 
six siblings, with whom she has distant relationships. The 
patient later reported that her uncle had vocal tics and fa-
cial grimacing and blinking, consistent with Tourette’s Syn-
drome. She stated that her father beat her up and slapped her 
face on both sides at age six, because she told her mother 
that the father had a girlfriend. She stated her father was the 
“chief and the family were the tribe”. She added that, while 
drunk, he would carry arrows and play a game, where he 
would squeeze her hand very hard.
Social history
The patient is a high school graduate with some college 
courses. She admitted to being distractible during grade 
school and would frequently be dreamy and look out the 
window. She has been married twice and has three children, 
one of whom is “problematic”. She is supported by Social 
Security Disability Insurance benefits.
Past medical history
The patient is status-post thyroidectomy, maintained on 
 synthroid. She also suffers from migraine headaches, terrify-
ing lucid dreams, and lactose intolerance. The patient drank 
alcohol daily. She denied a history of alcohol dependence 
in the past. She denied drug abuse in the past, although she 
admitted to the use of marijuana and overusing prescription 
medications. The patient is a non-smoker, who drinks two to 
three cups of tea and two to three cups of coffee a day.
Mental status examination
The patient was alert and oriented in all three spheres. Her 
mood was described as extremely depressed. She had sui-
cidal ideation, without plan. She had homicidal ideation, 
without plan. She denied auditory hallucinations, symptoms 
of OCD, delusions, or mania. She admitted to generalized 
anxiety as well as hyper-vigilance and daily lucid night-
mares during which she felt “helpless”. She reported daily 
flashbacks of earlier traumas and admitted to a history of 
burning herself with hot water or a hot knife. She ate three 
meals a day and slept only 0 to 2 hours.
Diagnosis
Axis I: Post-Traumatic Stress Disorder; Major Depressive 
Disorder; ADHD, inattentive type
Axis II: N/A
Axis III: obesity, s/p thyroidectomy
Axis IV: severe – symptom management
Axis V: CGAF 40
Initial treatment plan and progress notes
The patient was referred for individual therapy and for group 
Dialectical Behavioral Therapy (DBT). She was started on 
prazosin at bedtime. Her zoloft and seroquel doses were in-
creased.
Session 1
This session showed that the patient was alert, oriented and 
cooperative. She continued to complain of symptoms of 
PTSD. Her mood was extremely depressed, but her sleep 
and appetite were fair. She was being seen in DBT as well 
as individual psychotherapy. She had, for the first time, a 
dream about getting married again, which was interpreted 
by the psychiatrist as a possible sign of hopefulness, in con-
trast to her continuing dreams involving helplessness and 
hopelessness.
Session 2
The patient continued to complain of PTSD symptoms as 
well as those of depression. Her mood was only fair and 
there was no evidence of suicidal or homicidal ideation. Ap-
petite and sleep were normal. During this interview, she had 
recollections of her father masturbating her at four years of 
age and touching her behind. She also stated that her uncle 
had been more aggressive from ages 7 to 14 and forced her 
to have intercourse. Another uncle abused her from ages 10 
to 17. She reported feeling guilty about these experiences 
from the age of 7 onward.
Session 3
Her mood was normal, and there was no evidence of sui-
cidal or homicidal ideation nor manic changes. Her appetite 
was normal, but she continued to complain of “nightmares”. 
She had been started on prazosin, with the dose increased 
from 2 mg to 6 mg at bedtime.
Session 4
She complained of problems with her children but reported 
that her mood was essentially normal, and there was no evi-
dence of suicidality, homicidality, or nightmares. She did, 
in fact, report a decreased intensity in her dreams, which 
was coincident with the recently prescribed and increased 
adderall 20 mg in the morning.
Session 5
The patient complained of nightmares again, with a fair 
mood and no evidence of suicidal, homicidal, or manic 
symptoms. She continued individual and DBT. She thought 
that prazosin was making her nightmares worse. In par-
ticular, she described lucid dreams of an unpleasant nature. 
These dreams, upon further interrogation, were “as if I were 
fully awake” and had a very primal content involving rape 
and murder. Her prazosin, which she maintained was exac-
erbating her vivid, lucid, primal dreams was decreased to 
4 mg at bedtime. Prior to the next session, her visiting nurse 
stated that there was a need to decrease her prazosin further 
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because of an increase in her heart rate (reflex tachycardia). 
Xanax was given at bedtime in an attempt to alleviate the 
lucid dreams with traumatic content. The patient then re-
ported a lucid dream, wherein she was trying to dig out from 
behind a thick wall with a pick ax. She had opened up a 
hole in the wall but could not get her entire body through 
this hole. Her psychiatrist interpreted the hole as a sign of 
hope and speculated that the self-built wall represented the 
patient’s mistrust and strong defense against expressing any 
feelings or impulses (a character trait adopted since early 
childhood). Additionally, the interpretation was advanced 
that the responsibility for the wall and its erection was a 
decision of the patient.
Session 6
The patient stated her mood was depressed, but there was 
no evidence of suicidal or homicidal ideation nor mania. 
Lithium was started 300 mg for two days and then 600 mg a 
day thereafter as an augmenting strategy for her depression 
and because of her past history of suicidal preoccupations. 
The patient had been complaining of a head tremor, which 
she described as “internal” rather than external, and it was 
decided to discontinue her adderall. Her mood remained de-
pressed and she reported she had been dreaming about hav-
ing sex as a little girl with an older man, who resembled one 
of her uncles. She stated that she awoke suddenly and that 
her younger daughter with whom she slept (a cultural habit) 
stated that the patient had struck her in the head, apparently 
during one of these dreams.
Contact with the patient’s visiting nurse indicated that 
the patient was still complaining of “nightmares”, but that 
they had decreased with the initiation of clonidine 0.1 mg 
at bedtime (HS). Clonidine was then increased after a two-
week period to two pills at bedtime.
Session 7
The patient reported a depressed mood but no suicidal or 
homicidal ideation nor mania. She reported a lack of moti-
vation (consistent with her probable diagnosis of ADHD). 
She stated that she was having lucid sexual dreams again, 
in which she was “helpless”. She stated that there was no 
change in her internal head tremors. She had been referred 
to a local teaching hospital with an extended waiting pe-
riod. It was decided to discontinue her lithium, because she 
thought that these might be the source of her quasi-neuro-
logical symptoms.
Session 8
She had expressed a continued willingness to go for a neu-
rologic evaluation at a local teaching hospital. Her lithium 
continued to be titrated. She reported ongoing lucid dreams 
but was not specific about their content, although the explo-
ration of these was precluded by the limited time available 
during the visit.
Session 9
She reported that her youngest daughter (the one with whom 
she slept in a culturally familiar way) had been arrested and 
had to appear in court for attacking a fellow student, who 
had been bullying her. The patient reported a decrease in 
her head tremor and her mood was relatively normal. She 
reported that she was eating only one meal a day and had 
started taking KB220Z and noted decreased hunger on this 
nutraceutical. Off the adderall, her concentration had de-
creased somewhat. 
Session 10
The patient reported anxiety, apparently related to the fact 
that the local police had come to discuss a sexual assault on 
her oldest daughter (not the one she was sleeping with). She 
noted that while taking the KB220Z, her blood sugar had 
increased to 200, and she was placed on metformin but that 
her bad lucid dreams had become somewhat happier. Her 
nutraceutical (KB220Z which contained chromium) theo-
retically should not have increased her blood sugar. Never-
theless, her KB220Z was decreased to one pill in the morn-
ing and two at bedtime. 
Session 11
The patient reported being angry at a Motor Vehicle Agency 
representative but felt more motivated than she had after her 
adderall had been decreased. She stated that the combina-
tion of metformin and KB220Z was associated with a blood 
sugar decrease from 135 to 123 mg/ml. She stated at this 
point that she was only taking one KB220Z in the morning 
and one at bedtime and felt much calmer. She also reported 
that the content of her dreams had become “much happier”. 
In addition, she said that she was no longer having night-
mares or lucid dreams at all and that this had been the case 
for two months, which was coincident with the initiation of 
KB220Z. Her lucid dreams appeared to have satisfied the 
criteria of such dreams, since they were as if she were fully 
awake, were in vivid color and could be, to a certain extent, 
controlled by her voluntarily. Interestingly, the patient had 
missed the next few appointments because of transportation 
issues. She stated that during this time she had missed tak-
ing the KB220Z for three days and noted worsening lucid 
dreams, involving someone being raped. 
Session 12
The patient stated that her car had become more reliable as a 
means of transportation, and she no longer had to rely on the 
transportation service. She stated that her mood was normal 
and there was no evidence of suicidal or homicidal ideation 
nor mania. She stated that she was eating one meal a day 
(against medical advice but done by the patient in order to 
lose weight). Her weight was approximately 240 pounds. 
She was taking metformin twice a day. She had missed a 
few days of KB220Z and stated that her lucid and traumati-
cally terrifying dreams had returned. When she resumed 
taking three KB220Z a day, her vivid dreams persisted, but 
the content was not unpleasant. At one point, when she took 
four a day, these dreams continued to be lucid and had an 
unpleasant content, which could not be explored because 
of the length of the time available for the visit, however, 
excessive dopamine (homeostasis is required), as suggested 
earlier in this article, could be the associated issue. 
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Session 13
The patient expressed frustration with her visiting nurse. Her 
KB220Z continued to be prescribed at two tablets twice a day 
from the previous visit, and the patient reported that on a low-
er dose she had dreams of being raped but that this constituted 
the first truly bad dream of a lucid nature on this regimen.
Session 14
The patient complained about problems with her young-
est daughter who had been engaged in body piercing. She 
reported that her mood was depressed, that she had lost 
some weight, and that her dreams were normal on the four 
KB220Z a day, and that she was unable to remember any 
content, either pleasant or unpleasant. At this point, the pa-
tient wanted, because of an obsession about her weight and 
her resistance to following standard medical advice, to try 
a weight loss product known as Herbal Life. Because of 
possible but unknown interactions with the KB220Z, it was 
decided to discontinue the latter, for the time being. After a 
6-month period without KB220Z the terrifying lucid dreams 
returned again. However, when she began the KB220Z 
again within 2 weeks she reported no more terrifying lucid 
dreams (see Figure 1). 
Physical abuse history
The patient was verbally abused by her mother. She was 
sexually abused, at age 6, by a male babysitter. The latter 
was 17 years old. The patient remembered the perpetrator 
had a tendency to tap his hands. She informed her mother 
about the sexual abuse (which involved intercourse), and 
the perpetrator was arrested and incarcerated. The patient 
stated that this early abuse triggered the almost nightly oc-
currence of nightmares (four to five times a week) as well as 
frequent flashbacks. She added that her 22-year-old daugh-
ter had also been kidnapped and raped.
Family psychiatric history
Mother was an alcoholic, who died two years prior to the 
most recent intake. The patient reported she mourned her 
mother’s death. Her father, who was currently living in Tex-
as, had separated from her mother, when the patient was five 
years of age. 
ADHD history
The patient states that, during grade school, she was easily 
distracted as well as shy. She was spacey and dreamy rather 
than restless. She admitted to vocal tics, involving throat-
clearing. She reported a tendency to crack her bones, hands, 
ankles and wrists. She had a habit of blinking and would 
twist her neck and back frequently. 
Social history
She was a high school graduate with an Associate’s Degree. 
She had worked as a phlebotomist and medical assistant. 
She had not worked for three years and was not married, but 
had two children. She was separated from her 11-year-old 
daughter. 
Substance use history
The patient reported she had used cocaine daily for 11 years, 
totaling of between 3,000–4,000 hits. When asked how she 
felt after having taken cocaine, she stated “I felt level and 
normal”. This report appears to confirm the presence of 
RDS. The patient had used heroin for six or seven years as 
well. She denied the use of alcohol, angel dust, metham-
phetamine, LSD or ecstasy. 
Short term memory assessment
The patient stated that, upon entering a room, she would for-
get why she went there, on a daily basis. A similar lapse in 
short-term memory would occur daily, when she approached 
the refrigerator and wondered why she had gone there. She 
was able to remember names of people whom she knew but 
would frequently need to re-read material, even when the 
subject matter was not too complex, like the newspaper. 
She admitted to olfactory hallucinations involving “burning 
rubber” (a frequently noted symptom, with chronic cocaine 
users, noted by TM). She reported no other symptoms con-
sistent with temporal lobe epilepsy. She rated her concen-
tration ability as 30%, with maximum  concentration ability 
CASE PRESENTATION TWO
Identifying information and chief complaint
The patient DR is a 39-year-old woman, mother of two 
daughters, who lives with her boyfriend. She was referred by 
her therapist for psycho-pharmacology treatment and was at 
the same time attending a local methadone clinic. Her princi-
pal complaints involved an eating disorder (purging), depres-
sion, and symptoms consistent with PTSD. She was also opi-
oid-dependent. Her psychological symptoms included crying 
spells, depression, poor concentration, lack of appetite, rest-
lessness, panic attacks, purging, and cravings for drugs. 
Past history 
When seen initially the patient was being maintained on 
methadone 85 mg a day for her opioid dependence. She had 
been hospitalized, in the remote past, for a suicide attempt, 
by hanging. She had also been hospitalized at 20 years of 
age, for depression and ideas of reference.
Figure 1. Case One
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being 100%. Her procrastination tendency was 100% with 
maximum 100%. Her impulsiveness was 85% with maxi-
mum 100% and her boredom was 80% with maximum of 
100% based on a short memory questionnaire. 
Past medical history and reported allergies
The patient reported a history of Hepatitis C. Penicillin, 
macrobid, keflex, and trazodones were reported allergies 
(increased heart rate).
Mental status examination
The patient was alert and oriented in all three spheres. 
Her depression was rated as 10/10 (maximally depressed 
mood). She denied suicidal ideation, homicidal ideation, 
auditory or visual hallucinations. She admitted to olfactory 
hallucinations. She denied delusions but admitted to ideas 
of reference and a tendency towards obsessive compul-
sive disorder, wherein she felt compelled to wash the floor 
and bed continuously. She denied episodes of mania but 
reported a history of panic attacks and agoraphobia. She 
also reported that she slept three hours a night and would 
nap for three to four hours during the day. She admitted to 
almost nightly nightmares and daily flashbacks involving 
her sexual abuse. Her Dream Life is described in greater 
detail below.
Diagnostic impression
Axis I: Post-Traumatic Stress Disorder; Tourette’s Syn-
drome; ADHD; OCD, Panic Disorder, Major Depressive 
Disorder, Opioid Dependence, and Poly-substance Depend-
ence, by History
Axis II: NA
Axis III: Hepatitis C
Axis IV: Severe-Symptom management
Axis V: CGAF 35 
Treatment course
The patient was started on dextroamphetamine for her 
ADHD and Tourette’s Syndrome, prazosin for her night-
mares and flashbacks, sertraline for her depression, zolpi-
dem for her insomnia and gabapentin for her anxiety. On the 
next visit, her depression had been reduced to 7/10. She had 
stopped the dextroamphetamine 10 mg, because of feelings 
of agitation. She denied any drug use and was continuing 
her methadone treatment. There was some decrease in her 
flashbacks and nightmares. The antidepressants were in-
creased and her mood continued to improve. Although she 
had been using cocaine intermittently during her methadone 
treatment, she stated she had been able to stop its use for 
six weeks. She agreed to re-challenge with dextroampheta-
mine, which was slowly titrated. Clonidine was added for 
on-going nightmares. She became gradually less depressed, 
denying suicidal or homicidal ideation. Her concentration, 
procrastination, impulsiveness and boredom also improved 
on dextroamphetamine. She was maintained on methadone 
85 mg, at the local clinic. 
Subsequent sessions
She reported that she had developed pyelonephritis, which 
was successfully treated with antibiotics. Her concentration, 
procrastination, boredom, impulsiveness and mood contin-
ued to improve. The patient missed three sessions. During 
her next session, her mood was more depressed, and she 
admitted to auditory hallucinations. She had inexplicably 
stopped the dextroamphetamine for three weeks and was 
staying in bed, without any motivation. She reported ex-
treme boredom and procrastination. She stated that she had 
started using cocaine again and felt “more normal” when 
using it. She had been using cocaine for about ten days. 
Following her cessation of cocaine use, she felt “more de-
pressed”. She continued on methadone, 85 mg, at seven 
days a week. After a long hiatus, the patient reported that 
she had stopped taking her sertraline, dextroamphetamine, 
prazosin, clonidine, and gabapentin for six or seven weeks. 
Her mood had become severely depressed. She was eating 
half a meal a day and sleeping eight hours at a time, mostly 
out of boredom. She smoked 60% of the time, out of bore-
dom, and reported a return of her nightmares.
Medications were re-instituted, and she soon reported 
her mood had improved significantly. She admitted crav-
ings for drugs but denied any use. She was receiving weekly 
psychotherapy. Her concentration, procrastination, impul-
siveness and boredom were relatively improved. Because of 
side effects from the dextroamphetamine, she was eventu-
ally changed to the initial dose of lisdexamfetamine 30 mg. 
She continued on methadone 85 mg. Her mood was mod-
erately depressed. Concentration and impulsiveness were 
improved but procrastination and boredom remained poor 
during the lisdexamfetamine titration. She continued on clo-
nidine 0.1 mg at bed time, prazosin 2 mg at bed time, que-
tiapine 100 mg at bed time, sertraline 50 mg every morning, 
gabapentin 800mg four times a day, risperidone 1 mg at HS, 
alprazolam 0.5 mg three times a day and lisdexamfetamine 
30 mg a day.
Because of her frequent non-compliance and relapse 
with illicit drugs, she continued to attend her appointments 
irregularly. She had to be frequently re-started on her regi-
men, which had proven somewhat effective as long as she 
was compliant with it and avoided illicit drug use. At a later 
point, even though the patient had been off cocaine for two 
weeks, because of multiple, positive toxic urine screens for 
cocaine, her methadone was rapidly tapered from 75 mg a 
day by her clinic. At this point, she was sleeping only three 
hours a day and eating less than one meal a day.
She indicated she wanted to detoxify with subutex, 
maintaining she was allergic to suboxone. She stated that 
she was staying in bed and had no drive or motivation. She 
reported panic as well as ideas of reference. She was hav-
ing nightmares three to four times a week. Her concentra-
tion was dismal, with boredom and procrastination rated as 
maximally poor.
During the next session, her insurance company re-
quired a prior approval for her clonidine. She was now also 
being denied lisdexamfetamine, pending a prior approval. 
She appealed to the state Department of Public Health to 
prevent the rapid tapering of her methadone from 70 mg. 
She cited mental health reasons in her appeal. At this point, 
she was being seen on a weekly basis for medication man-
Putative dopamine agonist attenuates lucid nightmares in PTSD patients
 Journal of Behavioral Addictions 4(2), pp. 106–115 (2015) I 113
agement. She reported panic attacks as well as a lack of 
appetite but denied cravings for opiates or any use of other 
illicit drugs.
A letter was written to the state Department of Public 
Health in support of her appeal for a milder tapering of her 
methadone. The dopamine agonist, ropinorole, was then 
initiated along with lisdexamfetamine, which had been ap-
proved by the insurance company, so it was now possible to 
be increased to 70 mg a day. 
The patient was refused an extension by the Department 
of Mental Health and her rapid methadone tapering con-
tinued. During this period, her mood was moderately de-
pressed. She denied suicidal or homicidal ideation as well 
as hallucinations but complained of insomnia, involving six 
hours of sleep a night. She was eating only half a sandwich 
a day, despite urgings to increase per oral intake with sup-
plements like Ensure Plus.
The patient re-appeared after another six-week hiatus, 
stating that she had been now tapered to methadone 5 mg 
and had, in the intervening period, also been hospitalized 
for Methicillin-resistant Staphylococcus Aureus (MRSA). 
She stated that she was going through an agonizing with-
drawal, which involved thrashing her legs, vomiting, and 
severe diarrhea. 
Because of the refusal to obtain a slower tapering sched-
ule of methadone, the patient was offered KB220Z to assist 
in her withdrawal, while she awaited in-patient detoxifica-
tion with subutex. 
It has been reported that KB220Z can mitigate severe 
opiate withdrawal symptoms, in addition to improving oth-
er symptoms of Reward Deficiency Syndrome, as seen in 
ADHD and Tourette’s syndrome (Blum, Oscar-Berman et 
al., 2012). The patient was also urged to change insurance 
companies so that she could gain admission to an in-patient 
detoxification unit. This change was undertaken but would 
not be effective for another two weeks after her most recent 
visit. The patient stated, as had been her custom, that she 
had stopped the lisdexamfetamine, two weeks prior to the 
last visit, for unclear reasons.
She had been taking the KB220Z for two months and 
stated that she was now sleeping five hours a night as vs. 
one hour prior to that. She stated that her withdrawal symp-
toms had been improved by 40% and that she no longer had 
diarrhea or vomiting. She reported that she also no longer 
had nocturnal urinary incontinence, which she had suf-
fered, during her rapid, methadone withdrawal. She self-
increased her KB220Z from the initial dose of two tablets 
twice a day to five tablets a day and had done this two weeks 
prior to the last visit. 
Dream life
At this point, the patient spontaneously reported a change 
in the nature, content, and emotional tone of her dreams. 
With more pointed questioning, she reported that she had 
an onset of vivid (lucid), life-like dreams (“as if I am ful-
ly awake”) about three or four years prior to her current 
medication clinic intake. She stated that these dreams had 
been occurring on a three- to four-times-a-week basis. She 
reported that the prazosin had diminished her flashbacks 
and nightmares but that the addition of KB220Z made her 
“dreams almost fun!” She stated that her lucid dreams were 
“much happier now, with the exception of an occasional 
drug dream”. She stated that they remained lucid but that 
prior to the addition of the KB220Z, the dreams had been 
of a terrifying and Post-Traumatic-Stress-Disorder nature, 
involving, primarily, her sexual abuse. In addition, they had 
been uniformly terrifying and were almost always accom-
panied by an increased heart rate. The patient reported that, 
since the KB220Z had been added, “During my dreams, all 
I am doing is laughing!” 
This dream life, “Happiness Effect” had been going on 
for two months, since KB220Z had been added to her regi-
men. She even referred to nostalgic dreams of her mother, 
who had passed away two years prior, in which she would 
be affectionately calling her “Mommy”, as she had done as 
a little girl. There was no hint of sadness or grief in these 
reports of dreams about her mother. 
This case represents the second of two, serendipitous re-
ports in the change in the nature of lucid dreams of unpleas-
ant and terrifying content to dreams filled with happiness, 
laughter and nostalgia.
Limitations
The primary limitation to this present work is the very small 
number of patients. The other limitation is that this is not 
a double-blind randomized controlled placebo study and 
as such the results must be considered preliminary at best. 
Another caveat is that there was no standard evaluation of 
timing following the administration of KB220Z. Finally, 
because the patients were taking other known prescribed 
pharmaceuticals, albeit relief only followed the addition of 
KB220Z, we must caution these interesting results. 
DISCUSSION AND CONCLUSION
Both these patients were diagnosed with a form of RDS 
displaying ADHD symptomatology (Blum, Gardner et al., 
2012). They had a markedly improved effect on their almost 
lifelong, unpleasant, traumatic, lucid dreams. Such dreams 
were described as being extremely life-like (“as if I’m fully 
awake”). Other terms used were “in color”. As noted in the 
literature, such dreams can be re-initiated, if they are pleasant, 
after, for example, getting up at night to go to the bathroom 
or can be, on some occasions, voluntarily turned off by the 
dreamer, when they become extremely terrifying or traumatic.
These descriptions of the patients’ dreams seemed to fit 
the standard characteristics of lucid dreams. What is note-
Figure 2. Case Two
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worthy in both cases is that, at various times, because of 
the Reward Deficiency Syndrome-associated ADHD, the 
administered pharmaceuticals had no impact on the fre-
quency, vividness or unpleasantness of their lucid dreams. It 
was only when the KB220Z was added to her regimen that 
the frequency, intensity and nature of these dreams changed 
for more than 90% of the time in case 1; as noted above, 
the patient even stated that she had never had an extended 
period of happy dreams in her life and that one, in particular, 
involved a re-union with former office mates, where they 
were all partying joyfully together. Similar results were ob-
tained in case 2, whereby her dreams also became joyful and 
laughter-filled. 
It would appear that neither powerful antagonist(s) to 
norepinephrine/epinephrine; benzodiazepine agonist(s) & 
antagonist(s), anti-depressant(s); stimulant(s); dopamine 
D2 antagonist(s); noradrenergic-alpha2 agonist(s) in these 
two cases were responsible for this dramatic effect, nor their 
combination had any apparent effect on the lucidity or un-
pleasant content of their nightly dreams. A PubMed search 
of the combination of terms “dopamine and lucid dreams” 
produced no retrieved references (3-1-15).
There are a number of published papers that describe the 
ingredients in the KB220Z complex consisting of various 
precursor amino-acids for synthesis of serotonin, a chromi-
um salt; GABA and dopamine; a known natural enkephali-
nase inhibitor; a natural benzodiazepine stimulant and an 
herbal substance known to inhibit COMT and mitochondri-
al MAO-A (Blum, Femino et al., 2013). Following 27 clini-
cal trials with KB220 variants, since 1982, there is strong 
evidence that this complex, which was designed to mimic 
the “Brain Reward Cascade”, appears to increase dopamine 
release and activation across the Brain Reward Circuitry 
leading dopamine homeostasis (Blum et al., 2008). 
In fact, in human, neuro-imaging studies, KB220Z, com-
pared to placebo, demonstrated unequivocal evidence of ac-
tivation of the nucleus accumbens in heroin addicts (Blum, 
Oscar-Berman et al., 2013), using fMRI and quantitative 
EEG (qEEG) demonstrated regulation of widespread theta 
activity within the cingulate gyrus in abstinent, psycho-
stimulant addicts and increased alpha waves and low beta 
waves (Blum et al., 2010). Moreover, a recent experiment, 
using resting state fMRI, demonstrated functional connec-
tivity in rats clearly showing a selective robust activation 
of KB220Z over placebo. We found that connectivity with 
regions, such as the nucleus accumbens, the anterior cin-
gulate, pre-limbic and infra-limbic structures, was signifi-
cantly increased with KB220Z treatment. There was also 
evidence of recruitment of additional brain structures, such 
as the hippocampus, anterior thalamus, and somatosensory 
regions. We found similar results in abstinent heroin addicts 
where KB220Z also enhanced resting state functional con-
nectivity (Blum et al., 2015). These co-activated regions 
could constitute a statistical analogue of a neural network 
(McLaughlin et al., 1992), which, combined with specific, 
cortical loci, may be involved in the genesis of “nightmares” 
(Febo, Blum, Liu & Gold, 2014). 
In conclusion, the discovery that KB220Z increased func-
tional connectivity, has enormous implications for treatment 
of psychiatric diseases including RDS. The involvement of 
the above brain regions may imply induced dopaminergic 
homeostasis (redeeming joy) required to reduce unwanted 
lucid “bad dreams” in PTSD patients like AC and DR or 
from other causes (Hinton, Peou, Joshi, Nickerson & Si-
mon, 2013; Thompson & Pierce, 1999). 
In an unpublished work we have now observed relief 
of terrifying lucid dreams in twelve out of thirteen patients 
(92.3%) following KB220z at various time intervals. While 
these findings are encouraging they require cautious inter-
pretation and must await more intensive investigation in-
volving double-blinded experiments in a large population. 
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